Who is sponsoring NCT03115853?

NCT03115853 is sponsored by Vanderbilt University Medical Center.

What condition does NCT03115853 study?

NCT03115853 studies High Blood Pressure.

What drugs are being tested in NCT03115853?

Interventions: Aliskiren 150 mg, Placebo, HCTZ, Aliskiren 300 mg.

What is the status of NCT03115853?

NCT03115853 is currently COMPLETED.

Last reviewed 2017-07-25 · How we verify

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

NCT03115853 Phase 4 COMPLETED Results posted

Aliskiren (also called TekturnaTM) is a new drug for high blood pressure. Aliskiren works by blocking the actions of a substance called renin. Renin is a natural substance in the body that raises blood pressure. Renin is believed to contribute to the production of blood clots by increasing the amount of a substance known as Plasminogen Activator Inhibitor or PAI-1. This study will measure how aliskiren changes the amount of PAI-1 in the blood depending on the time of dosing. The purpose of this study is to find out if it is better to take aliskiren in the morning or at night.

Details

Lead sponsor	Vanderbilt University Medical Center
Phase	Phase 4
Status	COMPLETED
Enrolment	31
Start date	2009-06
Completion	2012-01

Conditions

High Blood Pressure

Interventions

Aliskiren 150 mg
Placebo
HCTZ
Aliskiren 300 mg

Primary outcomes

Difference in Peak Plasma PAI-1 Level — baseline to 18 weeks
Difference in Mean Plasma PAI-1 Level — baseline to 18 weeks

Countries

United States